TGFB2

(redirected from TGF-beta-2)

TGFB2

A gene on chromosome 1q41 that encodes a member of the transforming growth factor beta (TGFB) family of cytokines. These multifunctional peptides up- and downregulate proliferation, differentiation, adhesion, migration, death and other functions in many cell types. TGFBs transduce their signal by binding to transmembrane growth factor receptors (TGFBR1 and TGFBR2) and their downstream effectors, the SMAD proteins; disruption of the TGFB/SMAD pathway has been implicated in various cancers.
 
Molecular pathology
TGFB2  translocations to HDAC9 on chromosome 7 (t(1;7)(q41;p21)) is associated with Peters' anomaly, a congenital defect of the anterior chamber of the eye.
References in periodicals archive ?
for the development of SomatoKine for osteoporosis and a licensing agreement with Genzyme Corporation for the rights to TGF-beta-2 (transforming growth factor), currently in Phase II clinical testing for the treatment of dermal ulcers.
For the development of SomatoKine for osteoporsis and a licensing agreement with Genzyme Corporation for the rights to TGF-beta-2 (transforming growth factor), currently in Phase II clinical testing for the treatment of dermal ulcers.
for the development of SomatoKine, a recombinant DNA-derived protein complex, for osteoporosis and a licensing agreement with Genzyme Corporation for the rights to TGF-beta-2, (transforming growth factor) currently in Phase II clinical testing for the treatment of dermal ulcers.
In addition, Celtrix has licensed rights for another molecule, TGF-beta-2, currently in Phase II clinical testing for treatment of dermal ulcers, to Genzyme Corporation for incorporation into their comprehensive program for tissue repair.
TGF-beta-2 is currently in Phase II clinical testing for treatment of dermal ulcers.
Through strategic alliance with Celtrix, Genzyme Corporation is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease.
is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corporation is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease.
NASDAQ:CTRX) announced today that it has granted Genzyme Corporation's Tissue Repair Division (NASDAQ:GENZL) expanded technology and territory rights to recombinant TGF-beta-2, a therapeutic compound.
In addition, Genzyme now has the right to develop and commercialize TGF-beta-2 throughout the world, including Japan, China, Korea and Taiwan.
Genzyme received initial rights to Celtrix's recombinant TGF-beta-2 in June 1994 for all systemic and certain local treatment applications.
Expansion of Genzyme's technology and territory rights reflects our partner's continued interest in TGF-beta-2 and provides Celtrix with the opportunity for increased revenue from future milestone and royalty payments.
Through strategic alliances with Celtrix, The Green Cross Corporation is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corporation is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease.